The Biden administration, in what it called an “AI talent surge,” ushered in a wave of AI experts to various roles across the ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

The U.S. Food and Drug Administration said on Friday it issued new labeling changes for testosterone products based on ...

Dog owners can anticipate a new anti-aging pill that has achieved a key FDA milestone for efficacy, with expected market ...

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

NovoCure remains a strong buy with robust earnings, growth in cancer treatments, and significant upside potential to Wall ...

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...